US EditionPublished • loading... • Updated
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Investors who purchased Vistagen stock during the April 2024-Dec 2025 period must act by March 16 to seek lead plaintiff status in the securities fraud suit.
- On February 13, 2026, Rosen Law Firm reminded purchasers of Vistagen Therapeutics, Inc. common stock from April 1, 2024 through December 16, 2025 about the March 16, 2026 lead-plaintiff deadline in New York.
- Defendants allegedly issued optimistic statements while concealing material adverse facts about the PALISADE-3 Phase 3 study, which Vistagen disclosed failed its primary endpoint on December 17, 2025.
- Following the December 17, 2025 press release, investors can contact The Rosen Law Firm at Tel: 686-1060 or Toll Free: 866-767-3653 to join the lawsuit.
- If you suffered a loss in Vistagen, class members may recover without out-of-pocket costs through contingency fees and need not serve as lead plaintiff to share in any recovery.
- Rosen Law Firm highlights its record by noting it has been ranked in the top four since 2013 and recovered over $438 million in 2019, urging investors to choose qualified counsel.
Insights by Ground AI
13 Articles
13 Articles
Coverage Details
Total News Sources13
Leaning Left1Leaning Right1Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 20%
C 60%
R 20%
Factuality
To view factuality data please Upgrade to Premium
